Article and Video CATEGORIES
In Seattle, we just had an evening program for lung cancer awareness that included issues in lung cancer largely focused on rectifying the disparity in lung cancer funding and awareness compared with other cancers, but also on tobacco control and screening. One of the talks was by a pulmonologist colleague from the University of Washington, Dr. Jason Chien, who highlighted several notable points on smoking patterns and how they are related to risk of lung cancer.
The first point is that while we talk a lot about never-smokers with lung cancer, tobacco is still by far the most important risk factor contributing to lung cancer. Here's a list of other variables, which pale in their impact compared to tobacco ("relative risk" means the multiplier compared to someone without a risk factor, so a relative risk of 2 means that a person with that exposure has twice the risk of somoene without it):
Tragically, unlike most or perhaps all other deadly diseases in the world, lung cancer has a major industry promoting the exposure to this deadly risk factor:
Despite this force, smoking patterns have been declining over time, particularly in states in which there are stronger smoking cessation efforts, and less so in states that rely on tobacco as a leading component of their economy. Overall, it's about 20% overall and gradually declining over time:
This is largely because many people are quitting successfully, but as a side effect, there are growing ranks of ex-smokers in the US, now approaching 50 million. Fortunately, this has been associated with a significant decline in lung cancer deaths among men, and the start of a decline in lung cancer deaths now among women, who overall took up smoking later than men and have been a little slower to quit -- we hope the curves for women follow the decline seen in men over the next few decades:
Next, we'll turn to how much and how quickly the risk of smoking declines after a person quits smoking.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…